A pilot study of adjuvant chemotherapy with carboplatin and oral S ‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer

ConclusionsCarboplatin and oral S ‐1 had modest survival benefit, but this regimen was not tolerable in an adjuvant setting because fatal pulmonary embolism occurred in two patients.Key points Carboplatin and oral S ‐1 had modest survival benefit but this regimen was not tolerable. Fatal pulmonary embolism occurred in this regimen.

https://onlinelibrary.wiley.com/doi/abs/10.1111/1759-7714.13444?af=R

Source: Thoracic Cancer - April 28, 2020 Category: Cancer & Oncology Authors: Hisashi Tanaka, Chiori Tabe, Fumihiko Okumura, Toshihiro Shiratori, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Takeshi Morimoto, Daisuke Kimura, Takao Tsushima, Sadatomo Tasaka Tags: ORIGINAL ARTICLE Source Type: research